The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery
This prospective, multicentre, observational study aims to test pre-operative platelet function when taking anti-platelet medications. The investigators are using a simple bedside blood test called Thromboelastography (TEG) and Platelet Mapping Assay (PMA). The investigators will then follow the patient throughout their hospital stay for any major cardiac complications (MACE) after surgery (peri-operative). The investigators hope to determine if there is an association between how well platelets were inhibited by these drugs before surgery and MACE during the perioperative period, 30 day, and one year follow-up. Also, the response of various people to anti-platelet medications and their chances of getting a major adverse cardiac outcome are determined by their genetic makeup. The investigators will try to determine if certain genes are associated with higher cardiac risk.
Hypothesis: In patients who had percutaneous coronary intervention (PCI) and are undergoing non-cardiac surgery (NCS) major adverse cardiac events (MACE) are associated with inadequate platelet inhibition.
調査の概要
状態
条件
詳細な説明
Data analysis: The participants' demographics, preoperative characteristics and postoperative information will be summarized using descriptive statistics: expressed as mean (standard deviation) or median (minimum, maximum, interquartile range) for continuous variables and number (percent) for categorical variables. We will initially use restricted cubic spline plots to evaluate the nature of the association of platelet inhibition (continuous variable) and the risk of MACE (logit transformation). Based upon these results, we will determine if percent inhibition can be treated as a continuous variable, or whether it can be categorized along specific cut-offs. We will also compare these results against a receiver-operating-characteristic curve analysis. Once we have determined the appropriate approach for describing percent platelet inhibition, univariate analyses will be performed with chi-square or Fishers' exact test for categorical data, and t-test and Mann-Whitney U test for continuous data. A p < 0.05 will be considered statistically significant. Random effect multivariable logistic regression will be used to assess the adjusted association of platelet inhibition with MACE during the perioperative period.46 This regression model will employ a random intercept for each center, so as to minimize the bias due to any confounding by center.47 Regression models will be constructed to selectively include the potentially confounding perioperative variables that are associated with a higher risk of MACE (as identified from the literature and clinical experience).7-12 In addition to platelet inhibition (preoperative value or change), four covariates will be included in the model: type of stent; time between PCI and NCS; mono-, dual (aspirin or aspirin and clopidogrel) or no therapy until the day of surgery; and urgent surgery. Since the recommended range of platelet inhibition (20-50%)was never validated during the perioperative period we will describe it as a continuous variable (0-100%).
Primary analysis will be as per protocol the secondary analysis will include patients who have incomplete data i.e. discharged early or refused one or more TEG samples.
Sample Size: The sample size estimations were based on comparison of platelet inhibition (measures as a continuous variable) between individuals who did or did not suffer MACE. We assumed that the difference between the MACE and non-MACE groups with regard to platelet inhibition would correspond to a medium Cohen's effect size (0.5 SD; i.e. difference in means equaling 0.5 of the pooled standard deviation). Based on the assumption of the medium effect size difference, an expected 20% rate of MACE, a 2-sided alpha of 0.05, 90 % power, and a 10% dropout rate, we would need 189 patients in total. In addition, since our planned statistical model involves logistic regression with a total of five covariates (platelet inhibition value; stent type; emergency surgery; time between PCI and NCS; mono-, dual or no therapy after PCI [aspirin vs. aspirin and clopidogrel or no medications]) the sample size estimate would still have approximately 8 events per included covariate in the regression model. To minimize bias in the regression model, estimates recommend the minimum number of outcomes per covariate is 5-10.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Ontario
-
Toronto、Ontario、カナダ
- Toronto General Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Scheduled for non-cardiac surgery
- Has had PCI with: BMS within the last 24 months OR DES within any time frame
Exclusion criteria:
- Lack of informed consent
- Known clotting abnormality affecting any part of the clotting cascade
- Liver dysfunction with co-existing thrombocytopenia or INR > 1.4
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of patients with major adverse cardiac event (MACE)
時間枠:Measure will occure every day for 5 postoperative days
|
ECG daily for five days postoperatively Troponin measurements every 8 h +/- 1h for 6 measurements (first 48 hours postoperatively) then once daily till the fifth postoperative day. Patients will be assessed daily by study personnel for the presence of MACE (defined as death, ST or non-ST elevation myocardial infarction [MI], stent thrombosis or the need for repeat revascularization [PCI or coronary artery bypass grafting]transfusions, or the presence of bleeding complications. |
Measure will occure every day for 5 postoperative days
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- UHN090090BE
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。